Literature DB >> 319010

Recovery of hematologic competence without engraftment following attempted bone marrow transplantation for aplastic anemia: Report of a case with diffusion chamber studies.

L L Sensenbrenner, A A Steele, G W Santos.   

Abstract

An 18-year-old male with severe aplastic anemia associated with hepatitis was prepared for bone marrow transplantation with cyclophosphamide (50 mg/kg/day) for 4 consecutive days. He then received 3.47 X 10(8) nucleated bone marrow cells per kilogram of body weight from his HL-A identical sister by intravenous infusion. Although subsequent karyotyping showed that engraftment was not achieved, prompt hematologic recovery ensued by the third week post-transplant. Diffusion chamber culture of the patient's bone marrow stroma, obtained prior to cyclophosphamide therapy, was carried out. A prompt increase in the number of cells in the chambers was observed. A differential cell count of the contents was similar to that seen when normal bone marrow is cultured in a similar manner.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 319010

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  13 in total

Review 1.  Clinical management of aplastic anemia.

Authors:  Amy E Dezern; Robert A Brodsky
Journal:  Expert Rev Hematol       Date:  2011-04       Impact factor: 2.929

Review 2.  High-dose cyclophosphamide for autoimmunity and alloimmunity.

Authors:  Robert A Brodsky
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

3.  Complete remission of severe aplastic anaemia following treatment with anti-thymocyte globulin.

Authors:  M Griffin; L Coffey; S R McCann
Journal:  Ir J Med Sci       Date:  1983-08       Impact factor: 1.568

4.  Proceedings of the Annual Meeting of the European Foundation for Bone Marrow Transplantation, Sils Maria (Engadine), Switzerland, April 13-16, 1980.

Authors: 
Journal:  Blut       Date:  1980-09

Review 5.  Haematopoietic stem cell transplantation for autoimmune diseases.

Authors:  Joost F Swart; Eveline M Delemarre; Femke van Wijk; Jaap-Jan Boelens; Jürgen Kuball; Jacob M van Laar; Nico M Wulffraat
Journal:  Nat Rev Rheumatol       Date:  2017-02-23       Impact factor: 20.543

6.  Neutropenia in three patients with rheumatic disorders. Suppression of granulopoiesis by control-sensitive thymus-dependent lymphocytes.

Authors:  G C Bagby; J D Gabourel
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

Review 7.  Intensive immunosuppression with high dose cyclophosphamide but without stem cell rescue for severe autoimmunity: advantages and disadvantages.

Authors:  Robert A Brodsky; Richard J Jones
Journal:  Autoimmunity       Date:  2008-12       Impact factor: 2.815

8.  Treatment of aplastic anemia with a monoclonal antibody directed against the interleukin-2 receptor.

Authors:  W Schwinger; C Urban; H Lackner; C Mache
Journal:  Ann Hematol       Date:  1993-04       Impact factor: 3.673

9.  High-dose Cyclophosphamide is Effective Therapy for Pediatric Severe Aplastic Anemia.

Authors:  Christopher J Gamper; Clifford M Takemoto; Allen R Chen; Heather J Symons; David M Loeb; James F Casella; Amy E Dezern; Karen E King; Andrea M McGonigle; Richard J Jones; Robert A Brodsky
Journal:  J Pediatr Hematol Oncol       Date:  2016-11       Impact factor: 1.289

Review 10.  Cyclophosphamide and cancer: golden anniversary.

Authors:  Ashkan Emadi; Richard J Jones; Robert A Brodsky
Journal:  Nat Rev Clin Oncol       Date:  2009-09-29       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.